Le Lézard
Classified in: Health, Science and technology
Subjects: PDT, FDA

QIAGEN and Clinical Genomics Partner on Liquid Biopsies to Monitor Patients for Recurrence of Colorectal Cancer


HILDEN, Germany, GERMANTOWN, Maryland and BRIDGEWATER, New Jersey, August 21, 2017 /PRNewswire/ --

QIAGEN (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) and Clinical Genomics, a private company developing evidence-based diagnostic tools for colorectal cancer, today announced they have implemented the PAXgene® Blood ccfDNA Tube* sample collection in Clinical Genomics' Colveratm colorectal cancer ("CRC") recurrence assay. Colvera, an integrated liquid biopsy solution, is designed to enable easy and accurate monitoring for recurrence of colorectal cancer with a simple blood test collected in a physician's office.

"The Colvera test represents a unique opportunity for convenient, non-invasive monitoring of colorectal cancer patients by detecting methylated circulating tumor DNA that may indicate recurrence of a cancer. We are pleased to collaborate with Clinical Genomics in expanding the range of benefits made possible through liquid biopsies, which hold great promise for improving the lives of patients in cancer and other fields of medicine," said Thierry Bernard, Senior Vice President and Head of QIAGEN's Molecular Diagnostics Business Area.

"We are extremely pleased to use the highly automated QIAsymphony PAXgene Blood ccfDNA collection and sample processing workflow for collection and handling of Colvera samples. As a long-term commercial and research partner of QIAGEN, we have a great deal of confidence in this new solution," said Dr. Lawrence LaPointe, CEO of Clinical Genomics. "We are excited to roll out the PAXgene System as the front-end solution to allow physicians to provide Colvera testing to CRC patients as conveniently as possible. PAXgene allows a simple blood collection at the physician's office, with no on-site processing required, which is a great step forward from our alternative sample collection methods."

Click here for the full press release

http://corporate.qiagen.com/newsroom/press-releases/2017/2017-08-21-PAXgene-Colvera


Contacts: 
QIAGEN 
Investor Relations                     
John Gilardi 
+49-2103-291-1711        
e-mail:[email protected]

Public Relations
Dr. Thomas Theuringer
+49-2103- 291-1826
e-mail: [email protected] 

CLINICAL GENOMICS 
Media
Patty Jenkins        
+1-908-300-8673
e-mail:[email protected]
 

SOURCE QIAGEN N.V.


These press releases may also interest you

at 07:35
Ironwood Pharmaceuticals, Inc. , a GI-focused healthcare company, today announced positive, primary results up to Day 91 for its Phase II exploratory STARGAZE trial evaluating apraglutide in patients with steroid-refractory gastrointestinal acute...

at 07:35
The Real Brokerage Inc. , the fastest-growing, publicly traded brokerage, today announced that the Jon Campbell Team, formerly known as the Don Wenner Team, has joined the company. The team ranked as RealTrends' No. 1 Mega team in Pennsylvania and...

at 07:35
On March 21, xFusion Technologies International Co., Ltd. successfully hosted its Tech Summit 2024 and Partner Conference in Hong Kong. The conference focused on sharing industry trends and xFusion's product strategies centered around AI and green...

at 07:35
dentalcorp Holdings Ltd. ("dentalcorp" or the "Company") , Canada's largest and one of North America's fastest growing networks of dental practices, today announced that it will present at the following investor conferences: 2024 Bloom Burton & Co....

at 07:30
Quipt Home Medical Corp. (the "Company") ?, a U.S. based home medical equipment provider, focused on end-to-end respiratory care, today announced the voting results from its annual general and special meeting of shareholders held on March 27, 2024...

at 07:30
LeddarTech Holdings Inc. ("LeddarTech") , an automotive software company that provides patented disruptive AI-based low-level sensor fusion and perception software technology, LeddarVisiontm, for ADAS, AD and parking applications, is pleased to...



News published on and distributed by: